Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05064059
Title A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal adenocarcinoma

Therapies

Regorafenib + Trifluridine-tipiracil hydrochloride

MK-4280A

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Additional content available in CKB BOOST